Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia-Reference-Cited by-同舟云学术

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

Published:2012-07-19 Issue:2 Volume:31 Page:103-109
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematol Oncol

Author:

Latagliata Roberto¹,Breccia Massimo¹,Fava Carmen²,Stagno Fabio³,Tiribelli Mario⁴,Luciano Luigiana⁵,Gozzini Antonella⁶,Gugliotta Gabriele⁷,Annunziata Mario⁸,Cavazzini Francesco⁹,Ferrero Dario¹⁰,Musto Pellegrino¹¹,Capodanno Isabella¹²,Iurlo Alessandra¹³,Visani Giuseppe¹⁴,Crugnola Monica¹⁵,Calistri Elisabetta¹⁶,Castagnetti Fausto⁷,Vigneri Paolo³,Alimena Giuliana¹

Affiliation:

1. Department of Cellular Biotechnologies and Hematology; University ‘La Sapienza’; Rome; Italy

2. Division of Internal Medicine II; San Luigi Gonzaga Hospital; Orbassano; Italy

3. Hematology Division; Ferrarotto Hospital; Catania; Italy

4. Department of Hematology; University of Udine; Udine; Italy

5. Hematology; University ‘Federico II’; Naples; Italy

6. Hematology; University of Florence; Florence; Italy

7. Department of Hematology and Oncology ‘Seragnoli’; University of Bologna; Bologna; Italy

8. Hematology Division; Cardarelli Hospital; Naples; Italy

9. Hematology; University of Ferrara; Italy

10. Hematology Division; University of Turin; Italy

11. Onco-Hematologic Department; IRCCS Centro di Riferimento Oncologico della Basilicata; Rionero in Vulture; Italy

12. Hematology Division; Santa Maria Nuova Hospital; Reggio Emilia; Italy

13. Hematology Division; University of Milan; Italy

14. Hematology and Stem Cell Transplant Center; Marche Nord Hospital; Pesaro; Italy

15. Hematology Division; University of Parma; Italy

16. Hematology Division; Ca'Foncello Hospital; Treviso; Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2020/fullpdf

Reference19 articles.

1. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants;O'Hare;Cancer Res,2005

2. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants;Tokarski;Cancer Res,2006

3. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia;Kantarjian;N Engl J Med,2010

4. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy;Hochhaus;Blood,2007

5. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial;Kantarjian;Blood,2007

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study;BMJ Open;2023-08

2. Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies;Frontiers in Oncology;2023-02-06

3. Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance;International Journal of Molecular Sciences;2022-10-14

4. DASATINIB-INDUCED CHYLOTHORAX: A RARE CASE REPORT OF A 50-YEAR-OLD MAN WITH CHRONIC MYELOID LEUKEMIA;Chest;2022-10